• Of the NHL patients, 59 (44%) had diffuse large B-cell lymphoma (DLBCL). (smw.ch)
  • Treatment recommendations for patients with diffuse large B-cell lymphoma (DLBCL) begin with evaluating the extent of the disease, performance status of the patient, and histologic subtypes. (medscape.com)
  • Chimeric antigen receptor T (CART) cell therapy targeting the B cell specific differentiation antigen CD19 has shown clinical efficacy in a subset of relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL) patients. (frontiersin.org)
  • Blood cell and serum markers, along with clinical data of DLBCL patients who were scheduled for CART cell therapy were evaluated to search for biomarkers predicting CART cell responsiveness. (frontiersin.org)
  • Compared to healthy controls (n=24), DLBCL patients (n=33) showed significant lymphopenia, due to low CD3 + CD4 + T helper and CD3 - CD56 + NK cell counts, while cytotoxic CD3 + CD8 + T cell counts were similar. (frontiersin.org)
  • Low frequency of differentiated CD3 + CD27 - CD28 - T cells at leukapheresis represents a novel pre-infusion blood biomarker predicting a favorable response to CART cell treatment in r/r DLBCL patients. (frontiersin.org)
  • Diffuse large B cell lymphoma (DLBCL) represents the most frequent form of non-Hodgkin's lymphoma (NHL). (frontiersin.org)
  • Several factors hinder the identification of risk factors for central nervous system (CNS) involvement in diffuse large B-cell lymphoma (DLBCL), including the retrospective nature of most studies, the relatively low frequency of CNS relapse in DLBCL, and the heterogeneity of CNS prophylaxis methods used in these studies. (haematologica.org)
  • Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study. (canceropole-est.org)
  • Diffuse large B-cell lymphoma (DLBCL) is the most common form of NHL, accounting for more than 30 percent of newly diagnosed cases. (lymphomaindia.com)
  • Another example is "primary mediastinal B-cell lymphoma" which often occurs in younger patients and grows rapidly in the chest (mediastinum) Often, the first sign of DLBCL is a painless rapid swelling in the neck, armpit, or groin, which is caused by enlarged lymph nodes. (lymphomaindia.com)
  • Safety, tolerability, toxicity management, and supportive care are important aspects of patient counseling in the treatment of diffuse large B-cell lymphoma (DLBCL). (expertperspectives.com)
  • A study by Salles et al determined that correlations between specific biomarkers and the international prognostic index (IPI) score demonstrate that IPI remains the best available index in patients with DLBCL treated with rituximab and chemotherapy. (medscape.com)
  • Plutarch About 30% to 40% of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) experience relapse, and 10% are refractory to the. (ascopost.com)
  • FDA granted accelerated approval to glofitamab-gxbm (Columvi, Genentech, Inc.) for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. (org.in)
  • FDA granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. (org.in)
  • FDA approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.) with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. (org.in)
  • Besides modification based on a second-generation CAR, more advanced CAR-immune cell therapeutics are being tested, which utilize precise insertion of genes to circumvent graft-versus-host disease (GvHD) or employ a dual targeting approach and adapter CARs in order to avoid therapy resistance caused by antigen loss. (nature.com)
  • Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. (uchicago.edu)
  • Cycles are repeated every 14 days for 3 cycles, then high-dose chemotherapy with autologous stem-cell transplantation follows (if the patient is considered eligible for HDCT and ASCT). (wikipedia.org)
  • OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
  • Treatment selection takes into account patient age, fitness, and whether autologous stem cell transplantation (ASCT) is planned. (medscape.com)
  • We conducted a nationwide, multicenter, prospective registry study for newly diagnosed patients with peripheral T-cell lymphoma (PTCL) to better define the clinical characteristics, treatment patterns, survival outcomes, and the role of upfront autologous stem cell transplantation (ASCT) in these patients. (e-crt.org)
  • Objective To explore the prognostic evaluation of 18 F-FDG PET/CT imaging RECIL standard for patients with non-Hodgkin's lymphoma (NHL) after autologous hematopoietic stem cell transplantation (ASCT) and the comparative study with Lugano standard. (ijrmnm.com)
  • At this year's ASH meeting, data from the Phase 3 TOURMALINE-MM3 trial, evaluating the effect of NINLARO (ixazomib) as a maintenance therapy in adult patients diagnosed with multiple myeloma who responded to high-dose therapy (HDT) and autologous stem cell transplant (ASCT), will be presented for the first time during an oral session on Sunday, December 2 at 7:30 a.m. (covaipost.com)
  • The Dana-Farber/Boston Children's Stem Cell Transplant Center offers autologous and allogeneic stem cell transplants and is active in researching new stem cell techniques. (dana-farber.org)
  • The purpose of this study is to assess the effect your disease and the treatment of allogeneic stem cell transplant has upon you before and after your treatment process through questionnaires at certain time points. (mayo.edu)
  • The primary purpose of this study is to demonstrate the feasibility of sublingual (SL) administration of tacrolimus in blood and marrow transplant (BMT) patients. (mayo.edu)
  • The aim of this study is to measure the differences in quality of life and mood of hematopoietic stem cell transplant (HCT) patients and their caregivers staying at a hospital hospitality house (HHH), such as the Gift of Life Transplant House, the Help in Healing Home, and the Gabriel House of Care versus staying at a hotel/rental apartment or house. (mayo.edu)
  • Tandem haematopoietic stem cell transplantation versus single cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA. (canceropole-est.org)
  • This phase I/II trial studies the side effects and best dose of gene therapy in treating patients with human immunodeficiency virus (HIV)-related lymphoma that did not respond to therapy or came back after an original response receiving stem cell transplant. (ucdavis.edu)
  • This randomized phase III trial studies ibrutinib to see how well it works compared to placebo when given before and after stem cell transplant in treating patients with diffuse large B-cell lymphoma that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). (ucdavis.edu)
  • Before transplant, stem cells are taken from patients and stored. (ucdavis.edu)
  • It is not yet known whether adding ibrutinib to chemotherapy before and after stem cell transplant may help the transplant work better in patients with relapsed or refractory diffuse large B-cell lymphoma. (ucdavis.edu)
  • Is radioimmunotherapy before a donor peripheral blood stem cell transplant an effective treatment for non-Hodgkin's Lymphoma? (ucdavis.edu)
  • This phase II trial studies how well ibritumomab tiuxetan before donor peripheral blood stem cell transplant works in treating patients with relapsed or refractory non-Hodgkin lymphoma. (ucdavis.edu)
  • Giving rituximab, antithymocyte globulin, and total-lymphoid irradiation (TLI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells. (ucdavis.edu)
  • Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. (uchicago.edu)
  • Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. (uchicago.edu)
  • Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. (uchicago.edu)
  • Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. (uchicago.edu)
  • Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. (uchicago.edu)
  • Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. (uchicago.edu)
  • Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. (uchicago.edu)
  • T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. (uchicago.edu)
  • Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. (uchicago.edu)
  • What is an autologous stem cell transplant? (leukaemia.org.au)
  • Most people have a single autologous transplant. (leukaemia.org.au)
  • It's important to realise that the processes involved in a stem cell transplant are often long and complex. (leukaemia.org.au)
  • In the week leading up to your transplant you will be given a few days of very high-dose chemotherapy, and sometimes radiotherapy , to destroy your underlying disease. (leukaemia.org.au)
  • In the week following the transplant, your blood counts drop dramatically. (leukaemia.org.au)
  • Positive data from the TOURMALINE-MM3 trial, the first and only Phase 3 placebo-controlled study evaluating a proteasome inhibitor in this setting, showed that using NINLARO as a post-autologous stem cell transplant maintenance treatment improved progression-free survival over the control arm, highlighting NINLARO's potential use as a maintenance therapy in a patient population where there are currently limited options. (covaipost.com)
  • Dr. Abutalib is Assistant Director in the Stem Cell Transplant & Cell Therapy Program at Cancer Treatment Centers of America in Chicago. (ascopost.com)
  • This pilot clinical trial studies the side effects of irradiated donor cells following stem cell transplant in controlling cancer in patients with hematologic malignancies. (bioseek.eu)
  • Transfusion of irradiated donor cells (immune cells) from relatives may cause the patient's cancer to decrease in size and may help control cancer in patients receiving a stem cell transplant. (bioseek.eu)
  • Professor Ma holds leadership or scientific membership positions in a number of national and international scientific communities including the World Network for Blood & Marrow Transplantation (a WHO affiliated NGO), the AsiaPacific BM Transplant and the Royal College of Pathology of Australasian Quality Assurance Programme. (edu.au)
  • Biol Blood Marrow Transplant, 20(12): 2029-2033, 2014. (ycuhri.com)
  • Biol Blood Marrow Transplant, 20(5): 684-689, 2014. (ycuhri.com)
  • To investigate effects of the preautografting administration of rituximab on the mobilization and engraftment of peripheral blood stem cells (PBSC), we retrospectively analyzed the outcomes of 43 newly diagnosed diffuse-large B-cell lymphoma patients who received CHOP chemotherapy with or without rituximab as a first-line treatment before autologous PBSC transplantation (PBSCT). (elsevierpure.com)
  • 3 - 5 This report by the Spanish Lymphoma Group (GELTAMO) aims to provide useful guidelines and recommendations for the prevention, diagnosis, and treatment of central nervous system diffuse large B-cell lymphoma patients with, or at risk of, leptomeningeal and/or brain parenchyma lymphoma relapse. (haematologica.org)
  • Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry. (sc-ctsi.org)
  • ICE in the context of chemotherapy is an acronym for one of the chemotherapy regimens, used in salvage treatment of relapsed or refractory non-Hodgkin's lymphoma and Hodgkin lymphoma. (wikipedia.org)
  • [ 2 ] Options for second-line therapy in patients with relapsed/refractory disease include chemotherapy-free regimens with biologic targeted agents such as covalent Bruton tyrosine kinase (BTK) inhibitors, lenalidomide,venetoclax, and chimeric antigen receptor (CAR) T-cell therapy. (medscape.com)
  • Intensive chemotherapy regimens [ 7 ] and the use of new and more targeted therapeutic drugs have resulted in high cancer cure rates. (springeropen.com)
  • These are intensive chemotherapy regimens that, on one level, serve to identify patients who can tolerate such therapy, and they may offer potent cytoreduction, with the quality of remission being the biggest predictor of success with subsequent high-dose chemotherapy and autologous stem cell transplantation. (expertperspectives.com)
  • In case of CD20-positive B cell lymphoid malignancies the ICE regimen is often combined today with rituximab. (wikipedia.org)
  • There was no difference in the number of CD34 + cells among PBSC between the non-rituximab and the rituximab groups. (elsevierpure.com)
  • Although B-cells were completely depleted from PBSC in the rituximab group, we found no difference in the expression of CXCR-4, VLA-4 and c-Kit on PBSC, indicating that rituximab did not affect the expression of these adhesion molecules, which might be involved in the mechanism of mobilization. (elsevierpure.com)
  • Larger studies are required to determine the impact of rituximab on the mobilization and function of PBSC as well as whether a survival advantage exists in patients who undergo auto-PBSCT with rituximab. (elsevierpure.com)
  • Most important aspect of therapy is anti CD20 antibody, the Rituximab, which is a kind of immunotherapy or targeted therapy and attacks the CD20 antigen on the cancer cells. (lymphomaindia.com)
  • Rituximab should be combined with the chemotherapy for more efficient cancer cell kill. (lymphomaindia.com)
  • Radioimmunotherapy (RIT) alone or in combination with chemotherapy: Two radioimmunotherapy drugs are commercially available: Iodine 131 tositumomab (Bexxar) and Y90 ibritumomab tiuxetan (Zevalin). (lymphomaindia.com)
  • Additionally, the positive data from the ECHELON-2 trial demonstrated that in patients with previously untreated CD30-positive peripheral T-cell lymphoma, ADCETRIS in combination with chemotherapy was superior to the control arm for progression-free survival and overall survival, representing an important milestone for ADCETRIS as a potential therapy in this setting where standard of care has not changed in several decades. (covaipost.com)
  • In combination with chemotherapy, the checkpoint inhibitor is also showing value in the front-line setting and further boosting outcomes in the relapsed setting, according to. (ascopost.com)
  • The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. (smw.ch)
  • Despite this heterogeneous response, blood pre-infusion biomarkers predicting responsiveness to CART cell therapy are currently understudied. (frontiersin.org)
  • This is the first analysis to describe ATLL pathological features, cytogenetics, and response to standard therapy and transplantation in the Caribbean cohort. (oncotarget.com)
  • Radiation therapy has been used as part of the treatment for this lymphoma in adults but may not be necessary if high dose chemotherapy is used in the treatment plan. (dana-farber.org)
  • Non-Relapse Mortality after CAR T-Cell therapy for Large B-Cell Lymphoma: A LYSA Study from the DESCAR-T Registry. (canceropole-est.org)
  • Although most clinicians would agree that hematopoietic progenitor cell transplantation after reinduction therapy is frontline therapy for these patients, there is no consensus as to what type of hematopoietic progenitor cell transplantation promises the best event-free and overall survival. (jnccn.org)
  • This review outlines the disparate types of stem cell therapy that have been used in this difficult-to-treat population as well as the role of maintenance and CAR T-cell therapy in conjunction with stem cell therapy. (jnccn.org)
  • 1 - 3 However, those with relapsed and/or refractory (R/R) disease have had a historically dismal OS of ≤30% despite reinduction therapy and autologous hematopoietic progenitor cell transplantation (autoHCT) ( Figure 1 ). (jnccn.org)
  • HCT, whether it be autologous, allogeneic, or tandem, has been and continues to be an integral part of therapy, with varying outcomes as delineated in Table 2 . (jnccn.org)
  • and the role of CAR T-cell therapy as it relates to HCT as therapies for R/R B-NHL. (jnccn.org)
  • Kaplan-Meier curve showing probability of overall survival in children and adolescents with mature B-cell non‐Hodgkin's lymphoma with refractory or relapsed disease during or after therapy in the FAB/LMB96 international study. (jnccn.org)
  • Lately, CAR-NK cell therapies have also come into focus as novel therapeutic options to address hurdles related to CAR-T cell therapies, such as therapy-induced side effects. (nature.com)
  • Most CAR-T cell-based gene therapy products that are under clinical evaluation consist of autologous enriched T cells, whereas CAR-NK cell-based approaches can be generated from allogeneic donors. (nature.com)
  • The addition of separate adapter molecules (AMs) specific for tumor antigens and CAR-immune cells targeting these AMs allows a more precise and temporally limited therapy. (nature.com)
  • An autologous CAR-T or NK cell therapy comprises several steps as shown in Fig. 1 . (nature.com)
  • In gene therapy, small stretches of deoxyribonucleic acid (DNA) called 'anti-HIV genes' are introduced into the stem cells in the laboratory to make the gene therapy product used in this study. (ucdavis.edu)
  • The type of anti-HIV genes and therapy in this study may make the patient's immune cells more resistant to HIV-1 and prevent new immune cells from getting infected with HIV-1. (ucdavis.edu)
  • Case presentation Here, we report a case of a refractory MCL in a patient who had relapsed after conventional chemotherapy and autologous CAR T cell therapy. (bmj.com)
  • Conclusions This case suggests that haplo-CAR T cell therapy can be effective in controlling lymphoma that failed to respond to autologous CAR T cell therapy and overcome limitation of autologous CAR T cells, thus may be one possible regimen before the era of off-the-shelf "universal" CAR T cell therapy. (bmj.com)
  • Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. (uchicago.edu)
  • Regardless of prior allogeneic hematopoietic cell transplantation (allo-HCT) or pre-allo minimal residual disease (MRD) status, patients with newly diagnosed, FLT3 -ITD-positive acute myeloid leukemia (AML) in their first complete remission (CR1) were found to achieve superior overall survival (OS) when quizartinib (Vanflyta) was added to their standard intensive induction and consolidation therapy, according to data from post-hoc analyses of the phase 3 QuANTUM-First study (NCT02668653). (oncnursingnews.com)
  • There is an unmet need to develop novel therapies for refractory/relapsed MM. In the past few years, chimeric antigen receptor (CAR)-modified T cell therapy for MM has shown promising efficacy in preclinical and clinical studies. (biomedcentral.com)
  • Furthermore, the toxicities of CAR-T cell therapy are manageable. (biomedcentral.com)
  • Chimeric antigen receptor (CAR) T cell therapy has emerged as a novel immunotherapy which modifies T cells with CAR, an artificial fusion protein that incorporates an extracellular antigen recognition domain, a transmembrane domain, and an intracellular domain including costimulation and signaling components [ 4 , 5 ]. (biomedcentral.com)
  • Several antigens have been used as targets for CAR-T cell therapy against MM, including B cell maturation antigen (BCMA), CD19, CD138, signaling lymphocytic activation molecule 7 (SLAM7), and immunoglobulin light chains. (biomedcentral.com)
  • Two main advantages of BCMA as an antigen for CAR-T therapy are the potential reduction of on-target/off-tumor toxicity and the lack of antigen-dependent reduction in CAR-T cell expansion [ 16 ]. (biomedcentral.com)
  • the efficacy of the combination therapy is well demonstrated by large-scale studies, regardless of initial therapy or refractory/relapsed status ( N Engl J Med 372(2) (2015)">16 - Blood 131(3) (2018)">22 ). (cancerdiagnosisprognosis.org)
  • In a single-institution retrospective review reported in JAMA Oncology, Zurko et al found that early intrathecal therapy with hydrocortisone with or without intrathecal chemotherapy was effective in treating grade ≥ 3 immune effector cell-associated neurotoxicity syndrome (ICANS) in patients. (ascopost.com)
  • Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. (lookformedical.com)
  • FDA granted accelerated approval to elranatamab-bcmm (Elrexfio, Pfizer, Inc.), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (org.in)
  • FDA granted accelerated approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. (org.in)
  • FDA granted accelerated approval to mosunetuzumab-axgb (Lunsumio, Genentech, Inc.), a bispecific CD20-directed CD3 T-cell engager for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. (org.in)
  • Previously in July 2023, the FDA granted approval to the combination of quizartinib and standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation, for the treatment of adult patients with newly-diagnosed, FLT3 -ITD-positive AML based on published findings from QuANTUM-First. (oncnursingnews.com)
  • Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase, Blood Advances, Vol.7, No.6, 1019-1032, 2023. (matci.jp)
  • Mantle cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells localized in primary follicles or in the mantle region of secondary follicles. (medscape.com)
  • Mantle cell lymphoma (MCL) is recognized in the Revised European-American Lymphoma and World Health Organization classifications as a distinct clinicopathologic entity. (medscape.com)
  • Mantle cell lymphoma (MCL) is a type of non-Hodgkin B cell lymphoma with a distinctive molecular marker cyclin D1 that is constitutively overexpressed in almost all cases. (bmj.com)
  • The next-generation inhibitor of Bruton's tyrosine kinase (BTK) may be effective in mantle cell lymphoma for patients previously treated with an older BTK inhibitor, according to results from the phase I/II BRUIN trial. (ascopost.com)
  • The role of PD-1 and PD-L1 in T-cell immune suppression and the potential for immunotherapy via blocking PD-1 and PD-L1 in hematological malignancies are also reviewed. (biomedcentral.com)
  • Chimeric antigen receptor-modified T (CAR T) cells exhibit very effective function in elimination of relapsed/refractory B-cell lymphoid malignancies, we investigated their use in a patient with relapsed MCL. (bmj.com)
  • Khouri IF , Fernandez Curbelo I, Turturro F , Jabbour EJ , Bassett RL, Vence LM, Allison JP , Gulbis AM, Sharma P , Milton DR. Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. (viictr.org)
  • Several protocols of adjuvant therapies based on NK cell allo-reactivity have been extensively used in clinics for both hematologic and non-hematologic malignancies either alone or in combination with antibodies and tumor-sensitizing drugs. (biomedcentral.com)
  • I. To determine the toxicity associated with the administration of irradiated haploidentical cells (IHC) to patients with high-risk hematologic malignancies. (bioseek.eu)
  • High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (smw.ch)
  • High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. (smw.ch)
  • OBJECTIVE: To evaluate the use of high-dose sequential chemotherapy in a Brazilian population. (bvsalud.org)
  • Effects of hematopoietic stem cell adhesion on marrow stromal cell cytokine p. (rochester.edu)
  • Other risk factors for survival were primary refractory disease, initial lymphoma stage, number of previous chemotherapy lines, and high amounts of blood product transfusions. (smw.ch)
  • Treatment for primary central nervous system lymphoma requires high doses of chemotherapy that enter the central nervous system, such as high-dose methotrexate and high-dose cytarabine. (dana-farber.org)
  • Patients then receive high doses of chemotherapy to kill cancer cells and make room for healthy cells. (ucdavis.edu)
  • They are used to replace stem cells that have been damaged by high doses of chemotherapy , used to treat the patient's underlying disease. (leukaemia.org.au)
  • For decades the only available cancer treatments were surgical resection as well as chemotherapy and/or radiotherapy [ 1 ]. (nature.com)
  • During this time you are likely to be experiencing some of the common side effects of chemotherapy and radiotherapy which may include nausea, vomiting, mucositis (sore mouth) and bowel problems (diarrhoea). (leukaemia.org.au)
  • Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • For example, absolute lymphocyte counts (ALCs), a simple laboratory parameter that is routinely evaluated in the clinical setting, has been found to be associated with treatment outcomes in patients with diffuse large B cell lymphoma, follicular lymphoma, or acute leukemias ( Am J Hematol 84(2) (2009)">1 - Br J Haematol 134(6) (2006)">3 ). (cancerdiagnosisprognosis.org)
  • increased number of NK cells (particularly mature NK cells), helper T cells, and depleted Tregs can positively affect clinical outcomes ( Cancer Biomark 24(4) (2019)">4 - Leuk Res 66 (2018)">10 ). (cancerdiagnosisprognosis.org)
  • As reported in the Journal of Clinical Oncology by Teachey et al, the phase III Children's Oncology Group AALL1231 trial has shown that the addition of bortezomib to a modified augmented Berlin-Frankfurt-Münster (BFM) backbone improved survival outcomes in patients with newly diagnosed T-cell. (ascopost.com)
  • While the origin of these tumors is still not definitively known, the two theories with the most support suggest that these tumors arise from a primitive cell derived either from an embryologic tissue called the neural crest, or from resident cells in the body (called mesenchymal stem cells) that have a capability to become one of a variety of tissue types. (sarcomahelp.org)
  • Exosomes released from mesenchymal stem cells overexpressing microRNA-30e ameliorate heart failure in rats with myocardial infarction. (e-century.us)
  • Cancer immunotherapies aim to support or boost the patient's immune system to enable the effective clearance of cancer cells. (nature.com)
  • First, T or NK cells are isolated from patient's or donor's blood. (nature.com)
  • Stem cells are usually collected when the patient's disease is in remission or their disease is in a more stable state. (leukaemia.org.au)
  • Although children, adolescents, and young adults with newly diagnosed B-cell non-Hodgkin's lymphoma enjoy excellent overall survival with current chemoimmunotherapy, those with relapsed and/or refractory disease have a dismal prognosis. (jnccn.org)
  • Children, adolescents, and young adults (CAYAs) with newly diagnosed B-cell non-Hodgkin's lymphoma (B-NHL) enjoy excellent overall survival (OS) with current frontline chemoimmunotherapy. (jnccn.org)
  • The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. (lookformedical.com)
  • [ 2 ] It has become clear that AITL is a clonal T-cell disorder involving deregulation of B-cells and endothelial cells against a background involving a unique malignant microenvironment. (medscape.com)
  • Загальні відомості про лейкоз Leukemia is a malignant condition involving the excess production of immature or abnormal leukocytes, which eventually suppresses the production of normal blood cells and results in symptoms. (msdmanuals.com)
  • Normally, potentially malignant cells are continuously eliminated by the immune system, but cancer cells can accumulate certain mutations, which allow them to escape these mechanisms [ 2 ]. (nature.com)
  • CAR-modified immune cells are expanded until sufficient cell numbers are attained and are adoptively transferred into the patient to fight malignant cells. (nature.com)
  • BCMA, a member of the tumor necrosis factor (TNF) superfamily, is exclusively expressed in a subpopulation of B cells, normal plasma cells, and malignant plasma cells. (biomedcentral.com)
  • Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. (lookformedical.com)
  • His research focus is on haematopoietic stem cell transplantation (HSCT) and translational research of normal and malignant stem cells. (edu.au)
  • FDA approved quizartinib (Vanflyta, Daiichi Sankyo, Inc.) with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. (org.in)
  • Multiagent chemotherapy + immunotherapy should be reserved for patients who are having advanced stages of disease and having symptoms/ difficulties related to it. (lymphomaindia.com)
  • Immunotherapy utilizing T cell immunity has become a new treatment to eliminate cancer cells. (biomedcentral.com)
  • Among the different approaches of anti-tumor adoptive cell transfer, allogeneic stem cell transplantation (allo-SCT) represents the first and most consolidated form of immunotherapy on the basis of its graft versus tumor (GvT) effect. (biomedcentral.com)
  • Adult T-cell leukemia/lymphoma (ATLL) is a rare and aggressive disease caused by human T-cell lymphotropic virus type 1 that predominantly affects Japanese and Caribbean populations. (oncotarget.com)
  • With few exceptions, stem cell transplantation is usually reserved for patients with aggressive lymphomas after incomplete remission or relapse. (msdmanuals.com)
  • Approximately 30-40 % of patients with FL will eventually transform to a more aggressive form of lymphoma like Diffuse Large B Cell Lymphoma and may require intensive chemotherapy followed by autologous stem cell transplantation. (lymphomaindia.com)
  • Background The aggressive form of Mantle cell non-hodgkin B cell lymphoma (MCL) has a dismal prognosis. (bmj.com)
  • MCL can be both indolent or aggressive, in either case it responds poorly to chemotherapy and consequently the aggressive form has a dismal prognosis assessed by incorporating Ki-67 proliferation index and Mantle Cell International Prognostic Index scores. (bmj.com)
  • Autologous and allogeneic transplantation for aggressive NHL. (uchicago.edu)
  • HGBL, not otherwise specified (NOS) is a heterogeneous, aggressive, mature B-cell lymphoma that does not meet criteria for BL, DHL, or diffuse large B-cell lymphoma NOS. (cancernetwork.com)
  • The aggressive B-cell lymphomas BL, DHL, and HGBL, NOS are unique diseases with specific pathogenesis and biology. (cancernetwork.com)
  • 1 A significant minority of these cases were the especially aggressive B-cell lymphomas Burkitt lymphoma (BL) and high-grade B-cell lymphoma (HGBL), the latter of which includes the histologic subtypes HGBL with MYC and BCL2 and/or BCL6 translocations (conventionally referred to as double-hit lymphoma [DHL]) and HGBL, not otherwise specified (NOS). (cancernetwork.com)
  • Independent origins of fetal liver haematopoietic stem and progenitor cells. (u-tokyo-hemat.com)
  • Allogeneic transplantation was performed in five patients, two of whom achieved complete remission despite residual or refractory disease. (oncotarget.com)
  • These cells are collected in advance (while they are in remission ) and returned to the patient at a later stage. (leukaemia.org.au)
  • The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. (sc-ctsi.org)
  • The study will evaluate the safety, tolerability, and efficacy of autologous hematopoietic stem cell transplantation using BIVV003. (ucdavis.edu)
  • Although lenalidomide is considered to exert dual antitumor effects, including the activation of normal immune system through the activation of cytotoxic lymphocytes and the proteasome-dependent degradation of transcription factors such as IKZF1 and IKZF3 in myeloma cells ( J Mol Med (Berl) 94(12) (2016)">13 - Blood Rev 24(Suppl 1) (2010)">15 ), there is no clinical evidence that directly proves the association between changes in the profile of immune system and treatment efficacy in patients with MM treated with this agent. (cancerdiagnosisprognosis.org)
  • Aoki J, Kimura K, Kakihana K, Ohashi K, Sakamaki H: Efficacy and tolerability of Entecavir for hepatitis B virus infection after hematopoietic stem cell transplantation. (ycuhri.com)
  • Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
  • Validation of the ΔSUV for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial. (canceropole-est.org)
  • In this review, we are going to take a closer look at the commercial CAR-T cell therapies, as well as on CAR-T and CAR-NK cell products, which are currently under evaluation in clinical trials, that are being conducted in Germany. (nature.com)
  • With the presentation of data from two Phase 3 clinical trials as well as our pipeline, Takeda continues to grow the body of evidence for new therapeutic options that improve the way in which we treat blood cancer patients," said Christophe Bianchi, M.D., President, Takeda Global Oncology Business Unit. (covaipost.com)
  • The major risk with these procedures is the development of GVHD and several precautions have been put in place to avoid this unfavorable clinical event, such as the infusion of CD3 depleted high pure NK cells or the selection of HLA matched donors [ 8 ]. (biomedcentral.com)
  • BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. (uchicago.edu)
  • In autologous stem cell transplants, the patient is their own stem cell donor. (leukaemia.org.au)
  • Autologous transplants are used to treat a number of different blood cancers. (leukaemia.org.au)
  • Autologous transplants allow the use of high-dose chemotherapy, which provides some patients with a better chance of cure or long-term control of their disease. (leukaemia.org.au)
  • Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: a report from the FAB/LMB 96 study group. (jnccn.org)
  • After treatment, the stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. (ucdavis.edu)
  • Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis. (u-tokyo-hemat.com)
  • National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. (uchicago.edu)
  • After you have finished this treatment, your stem cells are thawed and reinfused through a vein into your bloodstream. (leukaemia.org.au)
  • Indeed, adoptive cell transfer of allogeneic NK cells have been used for the treatment of leukemia, colorectal cancer, hepatocellular cancer, lymphoma and melanoma. (biomedcentral.com)
  • I. To determine if treatment with the irradiated cells induces an immune response targeting tumor associated epitopes. (bioseek.eu)
  • Mesenchymal stem cell-derived exosomes: a promising vector in treatment for diabetes and its microvascular complications. (e-century.us)
  • Prompt Initiation of Conventional Chemotherapy to Avoid Early Death in Patients with Newly Diagnosed Acute Promyelocytic Leukemia. (u-tokyo-hemat.com)
  • When a patient is diagnosed with a blood cancer or chronic blood condition, it is often the start of a new journey that will be the beginning of great change. (rochester.edu)
  • The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. (oncotarget.com)
  • Children and teens with rare childhood non-Hodgkin lymphoma are treated at Dana-Farber/Boston Children's Cancer and Blood Disorders Center through the Childhood Lymphoma Program in our Childhood Hematologic Malignancy Center . (dana-farber.org)
  • CAR-expression on T or NK cells allows them to specifically target cancer cells via recognition of tumor associated antigens. (nature.com)
  • Ibrutinib is a drug that may stop the growth of cancer cells by blocking a protein that is needed for cell growth. (ucdavis.edu)
  • Also, radiolabeled monoclonal antibodies, such as ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. (ucdavis.edu)
  • Important insights into NK cell function in cancer eradication originated from the knowledge gained from mismatched NK cells in allo-SCT setting, where these innate immune effectors mediate a remarkable graft-versus-leukemia (GvL) effect towards tumor cells of recipient without attacking their normal tissues, thus limiting the onset of GVHD. (biomedcentral.com)
  • They look blue to a pathologist because of the staining that is used when identifying the cancer, so the cells are referred to as 'small round blue cells. (sarcomahelp.org)
  • Circular RNA circ_0084927 regulates proliferation, apoptosis, and invasion of breast cancer cells via miR-142-3p/ERC1 pathway. (e-century.us)
  • Professor Ma heads the Blood, Stem Cell and Cancer Research Programme at St Vincent's Centre for Applied Medical Research, Sydney. (edu.au)
  • Blood Cancer Journal, 4: e252, 2014. (ycuhri.com)
  • Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation. (uchicago.edu)
  • In the early 80s' donor lymphocyte infusions (DLI) with allo-activated haplo-identical cells from family members were infused in patients affected by hematological diseases or solid tumors. (biomedcentral.com)
  • Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful immunotherapeutic tools for combating hematological diseases confronted with pressing medical needs. (nature.com)
  • Three chimeric antigen receptor (CAR) T-cell therapies are approved by the US Food and Drug Administration in the third-line setting: axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. (expertperspectives.com)
  • One way to achieve this is to genetically modify immune cells, mainly T cells and recently also natural killer (NK) cells, to express chimeric antigen receptors (CARs). (nature.com)
  • Indeed, the use of check-point inhibitors, T cells with engineered chimeric antigen receptors (CARs) and bi-specific T cell engagers (BiTE) showed impressive therapeutic potentials in the cure of advanced tumors and are currently being included in the in the armamentarium of clinicians [ 1 ]. (biomedcentral.com)
  • Dana-Farber/Boston Children's offers internationally renowned care for children with cancers of the blood and immune system. (dana-farber.org)
  • 12 Sarah Cannon Research Institute and Tennessee Oncology Center for Blood Cancers, Nashville, Tennessee. (aacrjournals.org)
  • Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. (sc-ctsi.org)
  • There are also rare T-cell lymphomas that are more frequently seen in adults but occasionally occur in children. (dana-farber.org)
  • This is an open label, multicenter, Phase 1/2 study in approximately eight adults with severe Sickle Cell Disease (SCD). (ucdavis.edu)
  • The patient received multiple molecularly targeted therapies, including targeting BTK and BCL2, and haplo-identical CAR T (haplo-CAR T) cells from her daughter without previous allo-hematopoietic stem cell transplantation. (bmj.com)
  • Moreover, increasing data have shown that peripheral T-cell tolerance is an essential property of the specific immune response to tumor cells. (biomedcentral.com)
  • Agents in this class halt the cell cycle at the G1 phase in tumor cells. (medscape.com)
  • There was no difference in survival between patients who received chemotherapy alone versus chemotherapy with antiviral agents. (oncotarget.com)
  • Recipients of allogeneic transplantation had significantly improved overall survival compared to non-transplanted patients. (oncotarget.com)
  • As reported in The New England Journal of Medicine by Frederick L. Locke, MD, and colleagues, the phase III ZUMA-7 trial of patients with large B-cell lymphoma has shown improved event-free survival with second-line axicabtagene ciloleucel vs chemoimmunotherapy with high-dose chemotherapy and. (ascopost.com)
  • Prior to infusion of the CAR-modified immune cells, lymphodepletion is performed in most therapeutic settings to allow efficient cell engraftment [ 10 ]. (nature.com)